Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Merck & Co. Inc is a drug manufacturers-general business based in the US. Merck-and-CoInc shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Merck-and-CoInc employs 73,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $79.98 |
|---|---|
| 52-week range | $65.98 - $90.54 |
| 50-day moving average | $78.55 |
| 200-day moving average | $76.89 |
| Wall St. target price | $92.31 |
| PE ratio | 28.7156 |
| Dividend yield | $2.56 (3.39%) |
| Earnings per share (TTM) | $2.83 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $79.98 from 2022-01-21
| 1 week (2022-01-13) | -1.65% |
|---|---|
| 1 month (2021-12-21) | 5.88% |
| 3 months (2021-10-22) | -1.44% |
| 6 months (2021-07-22) | 4.51% |
| 1 year (2021-01-22) | -1.23% |
|---|---|
| 2 years (2020-01-22) | -10.72% |
| 3 years (2019-01-22) | 5.55% |
| 5 years (2017-01-20) | 28.00% |
Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Merck-and-CoInc shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1569. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.1 billion.
The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $52.6 billion |
|---|---|
| Operating margin TTM | 33.82% |
| Gross profit TTM | $34.6 billion |
| Return on assets TTM | 12.13% |
| Return on equity TTM | 26.04% |
| Profit margin | 13.68% |
| Book value | $14.17 |
| Market capitalisation | $205.6 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.
Merck & Co. Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.35 |
|---|---|
| Total ESG percentile | 47.16 |
| Environmental score | 3.15 |
| Environmental score percentile | 4 |
| Social score | 15.55 |
| Social score percentile | 4 |
| Governance score | 12.65 |
| Governance score percentile | 4 |
| Level of controversy | 3 |
Dividend payout ratio: 45.15% of net profits
Recently Merck-and-CoInc has paid out, on average, around 45.15% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.39% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.39% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.56 per share.
While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.
Merck-and-CoInc's most recent dividend payout was on 6 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2021 (the "ex-dividend date").
Merck-and-CoInc's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-CoInc shares which in turn could have impacted Merck-and-CoInc's share price.
Over the last 12 months, Merck-and-CoInc's shares have ranged in value from as little as $65.9822 up to $90.541. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4952. This would suggest that Merck-and-CoInc's shares are less volatile than average (for this exchange).
Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.